-
Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
•
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer’s letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products…
-
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
•
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced a strategic partnership with UK pharmaceutical giant AstraZeneca for the local manufacturing of Evusheld (tixagevimab, cilgavimab), a COVID-19 prophylactic neutralizing antibody combination. Financial details of the partnership were not disclosed. Drug ApprovalsEvusheld received Emergency Use…
-
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
•
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33 million on top of a USD100 million Series B financing round in October last year. The expanded funding included new investors such as Deep Track Capital and Piper Heartland Healthcare Capital. Proceeds will support key…
-
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
•
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10, its oral RNA-dependent RNA polymerase (RdRp) drug therapy for COVID-19. The National Medical Products Administration (NMPA) has accepted an Investigational New Drug (IND) filing for review, and the US Food and Drug Administration (FDA) has…
-
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
•
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC) PRO1184 in advanced tumors. The announcement was made alongside the appointment of Dr. Naomi Hunder as the company’s chief…
-
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
•
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48% year-on-year (YOY) increase in total global revenues to USD22.16 billion in constant currency terms. The company saw strong growth across various disease areas and key products. Business Performance Key Products COVID-19 Portfolio Geographical Performance Challenges…
-
Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion of patient enrollment in two Phase III trials for NVK-002, its core product for controlling myopia progression in children and adolescents. The studies, known as China CHAMP and Small CHAMP, mark a key milestone in…
-
Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study
•
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its drug LNK01004 for atopic dermatitis (AD). The drug was previously approved for a clinical trial in mild to moderate plaque psoriasis, with the first patient dosed…
